Screener
Praxis Precision Medicines, Inc. PRAX Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: Praxis Precision Medicines, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001689548-26-000083
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total operating expenses | 96,904 | 76,067 | 202,764 | 150,795 |
| Loss from operations | (96,904) | (76,067) | (202,764) | (150,795) |
| Other income: | ||||
| Other income, net | 13,184 | 4,940 | 26,483 | 10,372 |
| Total other income | 13,184 | 4,940 | 26,483 | 10,372 |
| Net loss | $(83,720) | $(71,127) | $(176,281) | $(140,423) |
| Net loss per share attributable to common stockholders, basic and diluted | $(2.87) | $(3.31) | $(6.08) | $(6.60) |
| Weighted average common shares outstanding, basic and diluted | 29,131,375 | 21,474,827 | 29,008,351 | 21,266,490 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Praxis Precision Medicines, Inc.'s other income, net (note 6)?
- Praxis Precision Medicines, Inc. (PRAX) reported other income, net (note 6) of $13.18M in Q2 2026.
- How has Praxis Precision Medicines, Inc.'s other income, net (note 6) changed year-over-year?
- Praxis Precision Medicines, Inc.'s other income, net (note 6) increased by 166.9% year-over-year, from $4.94M to $13.18M.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s other income, net (note 6)?
- Over 3 years (2022 to 2025), Praxis Precision Medicines, Inc.'s other income, net (note 6) has grown at a 188.3% compound annual growth rate (CAGR), from $957K to $22.93M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.
Ask your AI about Praxis Precision Medicines, Inc.'s other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude